EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Suppression of NSCLC progression via the co-administration of Danusertib, an AURK inhibitor, and KRIBB11, an HSF1 inhibitor

Xiang Zhang, Ying Lei, Xiang Chen, Jiahuang He, Zitian Liu, Wentao Zhu, Yi Xu, Xuru Jin

Biochemical Pharmacology · 2024

DOI: 10.1016/j.bcp.2024.116155 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Pharmacology, 2024. Verfasst von Xiang Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province 325000, China; Department of …. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Aminopyridines, Benzamides. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Wu Jieping Medical Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aurora kinase (AURK) and heat shock factor 1 (HSF1) are commonly overexpressed in non-small cell lung cancer (NSCLC), correlating with poor prognosis. This study aims to assess the therapeutic potential of combining the Danusertib (Danu, AURK inhibitor) and KRIBB11 (HSF1 inhibitor) for NSCLC treatment. The effects of this combination were investigated in A549 cells and a tumor xenograft mouse model. The findings demonstrate that concurrent administration of Danu and KRIBB11 effectively impedes cell proliferation, induces apoptosis, and triggers G2/M cell cycle arrest. Moreover, the combination treatment upregulates pro-apoptotic proteins (Cleaved-caspase3, Cleaved-PARP, and Bax) while downregulating anti-apoptotic proteins (Bcl-2), as well as G2/M-related proteins (CDC2 and cyclin B1). Additionally, the combination treatment elevates reactive oxygen species (ROS) levels, decreases mitochondrial membrane potential, and activates the DNA damage pathway. Interestingly, we discovered that the PI3K/AKT pathway is involved in mediating the effects of both Danu and KRIBB11. Furthermore, the combination treatment inhibits tumor growth and AKT signaling in the xenograft mouse model, increases levels of the tumor tissue oxidation product malondialdehyde (MDA), and induces DNA damage. To summarize, a potential therapeutic approach for NSCLC may involve dual inhibition of AURK and HSF1, resulting in the downregulation of the PI3K/AKT signaling pathway, and the activation of ROS-mediated mitochondrial and DNA damage pathways.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAminopyridinesBenzamidesIndazolesPyrazolesHumansAnimalsMiceProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesReactive Oxygen SpeciesCell ProliferationProtein Kinase InhibitorsApoptosisCell Line, Tumor

Stichwörter der Autor:innen

Aurora kinaseDanusertibHeat shock factor 1KRIBB11Non-small lung cell cancerPI3K/AKT

Substanzen

danusertibN2-(1H-indazole-5-yl)-N6-methyl-3-nitropyridine-2,6-diamineProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesReactive Oxygen SpeciesProtein Kinase InhibitorsAminopyridinesBenzamidesIndazolesPyrazoles

Autor:innen und Institutionen

  • Department of Thoracic Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province 325000, China; Department of Thoracic Surgery, The Quzhou Affiliated Hospital of Wenzhou Medical Un…
  • Department of Respiratory and Critical Care Medicine, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Ouzhou, Zhejiang Province 324000, China.
  • Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province 325000, China.
  • Department of Thoracic Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province 325000, China.
  • Department of Science & Technology, Department of Urology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Ouzhou, Zhejiang Province 324000, China. Electronic address: yixu.md@gma…
  • Department of Respiratory and Critical Care Medicine, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Ouzhou, Zhejiang Province 324000, China; Department of Respiratory and Critic…

Förderung

  • Wu Jieping Medical Foundation

Zitieren

APA

Zhang, X., Lei, Y., Chen, X., He, J., Liu, Z., Zhu, W., Xu, Y., & Jin, X. (2024). Suppression of NSCLC progression via the co-administration of Danusertib, an AURK inhibitor, and KRIBB11, an HSF1 inhibitor. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2024.116155

Vancouver

Zhang X, Lei Y, Chen X, He J, Liu Z, Zhu W, et al. Suppression of NSCLC progression via the co-administration of Danusertib, an AURK inhibitor, and KRIBB11, an HSF1 inhibitor. Biochemical Pharmacology. 2024. doi:10.1016/j.bcp.2024.116155

BibTeX
@article{Zhang2024,
  author = {Zhang, Xiang and Lei, Ying and Chen, Xiang and He, Jiahuang and Liu, Zitian and Zhu, Wentao and Xu, Yi and Jin, Xuru},
  title = {Suppression of NSCLC progression via the co-administration of Danusertib, an AURK inhibitor, and KRIBB11, an HSF1 inhibitor},
  journal = {Biochemical Pharmacology},
  year = {2024},
  doi = {10.1016/j.bcp.2024.116155}
}
Kostenlos starten →